PerindoprilThird Party Manufacturing in India

Perindopril is a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor administered as a prodrug that undergoes rapid hepatic hydrolysis to its active metabolite, perindoprilat. Perindoprilat exerts its antihypertensive effect by competitively inhibiting ACE, a peptidyl dipeptidase enzyme responsible for converting the inactive decapeptide angiotensin I into the potent vasoconstrictor angiotensin II. By blocking this conversion, perindoprilat reduces circulating angiotensin II levels, leading to decreased peripheral vasoconstriction and lower systemic vascular resistance. Additionally, reduced angiotensin II levels diminish aldosterone secretion from the adrenal cortex, resulting in decreased sodium and water retention, lower blood volume, and a further reduction in blood pressure.

ACE is identical to kininase II, the enzyme that degrades bradykinin, a potent vasodilator peptide. Perindoprilat-mediated ACE inhibition therefore also increases bradykinin levels, contributing to its vasodilatory effects through activation of the kallikrein-kinin system and subsequent prostaglandin release. This bradykinin potentiation is thought to partially account for the therapeutic efficacy of ACE inhibitors as well as their characteristic side effect of dry cough. Perindopril produces dose-dependent ACE inhibition of 80 to 90 percent at 8 mg, persisting for 10 to 12 hours, with approximately 60 percent inhibition maintained at 24 hours. Unlike some other ACE inhibitors, perindopril has a prolonged terminal elimination half-life of 30 to 120 hours due to slow dissociation from tissue ACE binding sites, allowing once-daily dosing with consistent 24-hour blood pressure control. Perindopril also demonstrates beneficial effects on vascular structure and function beyond blood pressure reduction, including regression of left ventricular hypertrophy and improvement in arterial compliance.

Therapeutic Uses

Perindopril is prescribed for the treatment of:

• Essential Hypertension: Perindopril is indicated for the treatment of mild to moderate essential hypertension, either alone or in combination with other antihypertensive agents such as thiazide diuretics or calcium channel blockers. It provides smooth, sustained blood pressure reduction over 24 hours with once-daily dosing.

• Congestive Heart Failure: Perindopril is indicated for the treatment of symptomatic heart failure, helping reduce morbidity and improve exercise tolerance. It is recommended as a first-line agent in patients with reduced left ventricular ejection fraction.

• Stable Coronary Artery Disease: Perindopril has been shown to reduce the risk of cardiovascular mortality, non-fatal myocardial infarction, and cardiac arrest in patients with a history of myocardial infarction or revascularization. The EUROPA study demonstrated significant cardiovascular event reduction with perindopril therapy.

• Stroke Prevention: By effectively controlling blood pressure and improving endothelial function, perindopril contributes to the primary and secondary prevention of cerebrovascular events.

• Diabetic Nephropathy: Perindopril provides renoprotective effects in patients with diabetic nephropathy, reducing proteinuria and slowing the progression of renal disease.

Why Manufacturers Choose Perindopril

Perindopril is a well-established ACE inhibitor with strong clinical evidence supporting its use in hypertension, heart failure, and coronary artery disease. The molecule is included in major international treatment guidelines and the WHO Essential Medicines List, ensuring consistent global demand. Indian manufacturers produce perindopril tablets for both the domestic market and export to regulated markets including Europe, the Middle East, and Asia. The availability of perindopril erbumine as the salt form allows for stable tablet formulations with good bioavailability. With the rising prevalence of hypertension and cardiovascular disease in developing countries, demand for affordable generic perindopril continues to grow, making it a reliable molecule for third party manufacturing in India and PCD franchise distribution networks.